Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon’s drug safety evaluation service successfully passed the CFDA review again

2015-08-26
|
Page View:

Last week, Medicilon’s pre-clinical drug safety evaluation service passed the CFDA inspection again. This time, the two Shanghai biopharmaceutical companies that have long-term cooperation with Medicilon passed the inspection.

Medicilon’s drug safety evaluation service successfully passed the CFDA review again

It is reported that the newly expanded preclinical drug safety evaluation laboratory of Medicipuya Pharmaceutical Technology (Shanghai) Co., Ltd. has been put into use in the second half of 2015. Take the special safety research service recognized by customers as an example (referring to No. 21 data in general). The main service content includes ASA, PCA, hemolysis and irritation tests, etc. The schedule has been nearly 4 months ahead of schedule. Can fully meet customer needs. According to researchers from Puya’s scientific research department, customers only need to do tests based on their needs to determine whether they need to do listing controls. If you can provide product manuals, it is better to conduct experiments after communicating and evaluating with our scientific research department.

If you want to know more about Medicilon’s pre-clinical services, please call 021-58591500-8957 or email to marketing@medicilon.com for business consultation.

Return
Relevant newsRelevant news